Appendix 4D & Half Yearly Report
Filed with ASX · · 20 pages · English
Watch Biome Australia's latest callBiome Australia (ASX:BIO) Q1 2026 Earnings Call · Replay · Oct 22, 2025Read the transcript of Biome Australia (ASX:BIO) Q1 2026 Earnings CallThe profit for the consolidated entity after providing for income tax amounted to $1,176,646 (31 December 2024: $433,395). Financial Performance Revenue for the half year increased 40% to $12.40m (1H25: $8.86m), driven by continued momentum across Biome's Activated Probiotics range and recently launched Activated Therapeutics. Gross margin remained strong at 61.1% (1H25: 61.0%). Net profit after t
In the deck
Earlier from Biome Australia
- Ethics Approval Granted for BMB18 Human Clinical Trial
- Biome secures distribution with Fullscript Canada
- Quarterly Activities & Cashflow Report
- Trading Update
- Biome Launches Human Clinical Trial on BMB18
Later from Biome Australia
- Biome First Half FY26 Results and Highlights
- Patent Application Filed for Probiotic Strain BMB18
- Probiotical Exclusive Supply Agreement Extended
- BMB18 clinical trial expands to dual site
- Biome Signs Australian Manufacturing Agreement
Follow Biome Australia into a list and get an email when it puts out news.
Follow Biome Australia